Premium
Peptide nucleic acid (PNA) probe‐based analysis to detect filaggrin mutations in atopic dermatitis patients
Author(s) -
Hwang Joonsung,
Lee Sangku,
Kim Daehwan,
Han Goeun,
Soung Nak Kyun,
ChaMolstad Hyunjoo,
Lee Kyung Ho,
Ryoo In Ja,
Ahn Mi Ja,
Kim Sung Tae,
Lee Min Jae,
Yoo Young Dong,
Lee Hee Gu,
Hong Jin Tae,
Kim Hyunjung,
Choi Eung Ho,
Kim SooChan,
Kwon Yong Tae,
Ahn Jong Seog,
Kim Bo Yeon
Publication year - 2018
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13765
Subject(s) - atopic dermatitis , filaggrin , peptide nucleic acid , nucleic acid , allele , mutant , medicine , microbiology and biotechnology , biology , genetics , immunology , gene
Atopic dermatitis ( AD ) is a chronic inflammatory skin disease whose prevalence is increasing worldwide. Filaggrin ( FLG ) is essential for the development of the skin barrier, and its genetic mutations are major predisposing factors for AD . In this study, we developed a convenient and practical method to detect FLG mutations in AD patients using peptide nucleic acid ( PNA ) probes labelled with fluorescent markers for rapid analysis. Fluorescence melting curve analysis ( FMCA ) precisely identified FLG mutations based on the distinct difference in the melting temperatures of the wild‐type and mutant allele. Moreover, PNA probe‐based FMCA easily and accurately verified patient samples with both heterozygote and homozygote FLG mutations, providing a high‐throughput method to reliable screen AD patients. Our method provides a convenient, rapid and accurate diagnostic tool to identify potential AD patients allowing for early preventive treatment, leading to lower incidence rates of AD , and reducing total healthcare expenses.